RxDoctor Payments Data

John Tsakonas, MD

Cardiovascular Disease · Encino, CANPI 1851384499

Payments from drug & device makers

$542in general payments, 2019–2025

Across 24 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$151
  • Medtronic$149
  • Johnson & Johnson$72
  • Amgen$48
  • Heartflow, Inc.$39
  • Boehringer Ingelheim$34
  • plus $49 from 2 others

What the payments were for

  • Food & beverage$542100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$542 in reported general payments places this provider in the 25th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$272,516
Medicare patients
623
Services billed
1,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$155,088
EntrestoSacubitril/Valsartan32$45,488
XareltoRivaroxaban12$16,179
Metoprolol Succinate311$5,211
Atorvastatin Calcium159$1,175
Ezetimibe47$1,058
Rosuvastatin Calcium63$962
Potassium Chloride32$791
Pravastatin Sodium37$590
Digoxin34$568
Amlodipine Besylate55$529
Isosorbide Mononitrate ErIsosorbide Mononitrate33$461
Furosemide102$409
ClopidogrelClopidogrel Bisulfate32$381
Losartan Potassium25$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$151$45,48832 claims
Johnson & JohnsonXarelto$72$16,17912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →